Ex vivo TKI sensitivity of ABL-class ALL samples. (A-C) Z-score of the area under the dose-response curve (AUC) for imatinib, dasatinib, and bosutinib sensitivity, respectively, of primary and primary xenografted ALL samples with ABL-class fusions compared with primary and primary xenograft ALL samples of pediatric BCR::ABL1-positive ALL. (D-E) Correlation between sensitivity to imatinib (ima) and dasatinib (dasa) or bosutinib (bosu). The Spearman correlation coefficient (Rho) is calculated for the reference cohort of BCR::ABL1-positive ALL samples. The x = y line is displayed in gray. (F-G) Correlation between imatinib and dasatinib or bosutinib in ABL1- or PDGFRB-fused ALL samples, respectively. The Spearman correlation coefficient (Rho) and P value are calculated and are displayed in the tables below.